Global pharma company Jazz Pharmaceuticals has ended patent claims related to its cannabinoid-based epilepsy drug, Epidiolex.
Pharma giant Jazz dismisses final patent claim involving cannabinoid epilepsy drug is a post from: MJBizDaily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs